Specific increase in potency via structure-based design of a TCR

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2587-2599

  Malecek, Karolina ^a   Grigoryan, Arsen ^a   Zhong, Shi ^a,d   Gu, Wei Jun ^b   Johnson, Laura A ^c,e   Rosenberg, Steven A ^c   Cardozo, Timothy ^a   Krogsgaard, Michelle ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Guangzhou Institute of Microbiology Group Co   (China)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DMF 4; DMF 5; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; IMMUNE RESPONSE; MOLECULAR MODEL; MOUSE; NONHUMAN; POINT MUTATION; RECEPTOR AFFINITY; STRUCTURE ANALYSIS; T LYMPHOCYTE ACTIVATION; ANIMAL; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOCYTE ACTIVATION; MART-1 ANTIGEN; PEPTIDES; POINT MUTATION; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907029434     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302344     Document Type: Article

References (101)

1. Stone, J. D., A. S. Chervin, and D. M. Kranz. 2009. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126: 165-176.
2. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
3. Kim, P. S., and R. Ahmed. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22: 223-230.
4. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
5. Rosenberg, S. A. 2012. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 4: 127ps8.
6. Leen, A. M., C. M. Rooney, and A. E. Foster. 2007. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25: 243-265.
7. Davis, M. M., and P. J. Bjorkman. 1988. T-cell antigen receptor genes and Tcell recognition. Nature 334: 395-402.
8. Willcox, B. E., G. F. Gao, J. R. Wyer, J. E. Ladbury, J. I. Bell, B. K. Jakobsen, and P. A. van der Merwe. 1999. TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity 10: 357-365.
9. Zhong, S., K. Malecek, L. A. Johnson, Z. Yu, E. Vega-Saenz de Miera, F. Darvishian, K. McGary, K. Huang, J. Boyer, E. Corse, et al. 2013. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in Tcell immunotherapy. Proc. Natl. Acad. Sci. USA 110: 6973-6978.
10. Davis, M. M., J. J. Boniface, Z. Reich, D. Lyons, J. Hampl, B. Arden, and Y. Chien. 1998. Ligand recognition by ab T cell receptors. Annu. Rev. Immunol. 16: 523-544.
11. Schmid, D. A., M. B. Irving, V. Posevitz, M. Hebeisen, A. Posevitz-Fejfar, J. C. Sarria, R. Gomez-Eerland, M. Thome, T. N. Schumacher, P. Romero, et al. 2010. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184: 4936-4946.
12. Rudolph, M. G., R. L. Stanfield, and I. A. Wilson. 2006. How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24: 419-466.
13. Arstila, T. P., A. Casrouge, V. Baron, J. Even, J. Kanellopoulos, and P. Kourilsky. 1999. A direct estimate of the human αβ T cell receptor diversity. Science 286: 958-961.
14. Mason, D. 1998. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19: 395-404.
15. Wilson, D. B., D. H. Wilson, K. Schroder, C. Pinilla, S. Blondelle, R. A. Houghten, and K. C. Garcia. 2004. Specificity and degeneracy of T cells. Mol. Immunol. 40: 1047-1055.
16. Wooldridge, L., J. Ekeruche-Makinde, H. A. van den Berg, A. Skowera, J. J. Miles, M. P. Tan, G. Dolton, M. Clement, S. Llewellyn-Lacey, D. A. Price, et al. 2012. A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 287: 1168-1177.
17. Sewell, A. K. 2012. Why must T cells be cross-reactive? Nat. Rev. Immunol. 12: 669-677.
18. Wucherpfennig, K. W. 2004. T cell receptor crossreactivity as a general property of T cell recognition. Mol. Immunol. 40: 1009-1017.
19. Wilson, D. B., C. Pinilla, D. H. Wilson, K. Schroder, C. Boggiano, V. Judkowski, J. Kaye, B. Hemmer, R. Martin, and R. A. Houghten. 1999. Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. J. Immunol. 163: 6424-6434.
20. Hemmer, B., M. Vergelli, C. Pinilla, R. Houghten, and R. Martin. 1998. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol. Today 19: 163-168.
21. Garcia, K. C., M. Degano, L. R. Pease, M. Huang, P. A. Peterson, L. Teyton, and I. A. Wilson. 1998. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279: 1166-1172.
22. Caspi, R. R. 2008. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 8: 970-976.
23. Deng, L., R. J. Langley, P. H. Brown, G. Xu, L. Teng, Q. Wang, M. I. Gonzales, G. G. Callender, M. I. Nishimura, S. L. Topalian, and R. A. Mariuzza. 2007. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat. Immunol. 8: 398-408.
24. Nicholson, M. J., M. Hahn, and K. W. Wucherpfennig. 2005. Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Immunity 23: 351-360.
25. Hahn, M., M. J. Nicholson, J. Pyrdol, and K. W. Wucherpfennig. 2005. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol. 6: 490-496.
26. Wucherpfennig, K. W., and J. L. Strominger. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80: 695-705.
27. Holler, P. D., P. O. Holman, E. V. Shusta, S. O'Herrin, K. D. Wittrup, and D. M. Kranz. 2000. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 97: 5387-5392.
28. Chlewicki, L. K., P. D. Holler, B. C. Monti, M. R. Clutter, and D. M. Kranz. 2005. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J. Mol. Biol. 346: 223-239.
29. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23: 349-354.
30. Kessels, H. W., M. D. van Den Boom, H. Spits, E. Hooijberg, and T. N. Schumacher. 2000. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA 97: 14578-14583.
31. Chervin, A. S., D. H. Aggen, J. M. Raseman, and D. M. Kranz. 2008. Engineering higher affinity T cell receptors using a T cell display system. J. Immunol. Methods 339: 175-184.
32. Bowerman, N. A., T. S. Crofts, L. Chlewicki, P. Do, B. M. Baker, K. Christopher Garcia, and D. M. Kranz. 2009. Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. Mol. Immunol. 46: 3000-3008.
33. Shusta, E. V., M. C. Kieke, E. Parke, D. M. Kranz, and K. D. Wittrup. 1999. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J. Mol. Biol. 292: 949-956.
34. Malecek, K., S. Zhong, K. McGary, C. Yu, K. Huang, L. A. Johnson, S. A. Rosenberg, and M. Krogsgaard. 2013. Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. J. Immunol. Methods 392: 1-11.
35. Haidar, J. N., B. Pierce, Y. Yu, W. Tong, M. Li, and Z. Weng. 2009. Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins 74: 948-960.
36. Alli, R., Z. M. Zhang, P. Nguyen, J. J. Zheng, and T. L. Geiger. 2011. Rational design of T cell receptors with enhanced sensitivity for antigen. PLoS ONE 6: e18027.
37. Hawse, W. F., M. M. Champion, M. V. Joyce, L. M. Hellman, M. Hossain, V. Ryan, B. G. Pierce, Z. Weng, and B. M. Baker. 2012. Cutting edge: evidence for a dynamically driven T cell signaling mechanism. J. Immunol. 188: 5819-5823.
38. Holler, P. D., L. K. Chlewicki, and D. M. Kranz. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4: 55-62.
39. Schmitt, T. M., D. H. Aggen, I. M. Stromnes, M. L. Dossett, S. A. Richman, D. M. Kranz, and P. D. Greenberg. 2013. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood 122: 348-356.
40. Linette, G. P., E. A. Stadtmauer, M. V. Maus, A. P. Rapoport, B. L. Levine, L. Emery, L. Litzky, A. Bagg, B. M. Carreno, P. J. Cimino, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863-871.
41. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352.
42. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumorinfiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91: 6458-6462.
43. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758.
44. Cole, D. K., E. S. Edwards, K. K. Wynn, M. Clement, J. J. Miles, K. Ladell, J. Ekeruche, E. Gostick, K. J. Adams, A. Skowera, et al. 2010. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J. Immunol. 185: 2600-2610.
45. Miles, K. M., J. J. Miles, F. Madura, A. K. Sewell, and D. K. Cole. 2011. Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol. Immunol. 48: 728-732.
46. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
47. Borbulevych, O. Y., S. M. Santhanagopolan, M. Hossain, and B. M. Baker. 2011. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J. Immunol. 187: 2453-2463.
48. Johnson, L. A., B. Heemskerk, D. J. Powell, Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg. 2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177: 6548-6559.
49. Morgan, R. A., N. Chinnasamy, D. Abate-Daga, A. Gros, P. F. Robbins, Z. Zheng, M. E. Dudley, S. A. Feldman, J. C. Yang, R. M. Sherry, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36: 133-151.
50. Boon, T., P. Coulie, M. Marchand, P. Weynants, T. Wölfel, and V. Brichard. 1994. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv. Oncol. 1994: 53-69.
51. Zarour, H., C. De Smet, F. Lehmann, M. Marchand, B. Lethé, P. Romero, T. Boon, and J. C. Renauld. 1996. The majority of autologous cytolytic Tlymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J. Invest. Dermatol. 107: 63-67.
52. Cohen, C. J., Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66: 8878-8886.
53. Szymczak, A. L., and D. A. Vignali. 2005. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin. Biol. Ther. 5: 627-638.
54. Letourneur, F., and B. Malissen. 1989. Derivation of a T cell hybridoma variant deprived of functional T cell receptor a and b chain transcripts reveals a nonfunctional a-mRNA of BW5147 origin. Eur. J. Immunol. 19: 2269-2274.
55. Barnea, E., I. Beer, R. Patoka, T. Ziv, O. Kessler, E. Tzehoval, L. Eisenbach, N. Zavazava, and A. Admon. 2002. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur. J. Immunol. 32: 213-222.
56. Juang, J., P. J. Ebert, D. Feng, K. C. Garcia, M. Krogsgaard, and M. M. Davis. 2010. Peptide-MHC heterodimers show that thymic positive selection requires a more restricted set of self-peptides than negative selection. J. Exp. Med. 207: 1223-1234.
57. Krogsgaard, M., N. Prado, E. J. Adams, X. L. He, D. C. Chow, D. B. Wilson, K. C. Garcia, and M. M. Davis. 2003. Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol. Cell 12: 1367-1378.
58. Laugel, B., H. A. van den Berg, E. Gostick, D. K. Cole, L. Wooldridge, J. Boulter, A. Milicic, D. A. Price, and A. K. Sewell. 2007. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J. Biol. Chem. 282: 23799-23810.
59. Labarriere, N., E. Diez, M. C. Pandolfino, C. Viret, Y. Guilloux, S. Le Guiner, J. F. Fonteneau, B. Dreno, and F. Jotereau. 1997. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J. Immunol. 158: 1238-1245.
60. Zhong, S., K. Malecek, A. Perez-Garcia, and M. Krogsgaard. 2010. Retroviral transduction of T-cell receptors in mouse T-cells. J. Vis. Exp. 44: 2307.
61. Zhao, Y., Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan. 2005. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174: 4415-4423.
62. Kerkar, S. P., L. Sanchez-Perez, S. Yang, Z. A. Borman, P. Muranski, Y. Ji, D. Chinnasamy, A. D. Kaiser, C. S. Hinrichs, C. A. Klebanoff, et al. 2011. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J. Immunother. 34: 343-352.
63. Savage, P. A., J. J. Boniface, and M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10: 485-492.
64. Abagyan, R., M. Totrov, and D. Kuznetsov. 1994. ICM: a new method for protein modeling and design-applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 15: 488-506.
65. Abagyan, R., and M. Totrov. 1994. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235: 983-1002.
66. Abagyan, R. A., and M. Totrov. 1999. Ab initio folding of peptides by the optimal-bias Monte Carlo minimization procedure. J. Comput. Phys. 151: 402-421.
67. Schapira, M., M. Totrov, and R. Abagyan. 1999. Prediction of the binding energy for small molecules, peptides and proteins. J. Mol. Recognit. 12: 177-190.
68. Zhong, S., K. Malecek, L. A. Johnson, Z. Yu, E. Vega-Saenz de Miera, F. Darvishian, K. McGary, K. Huang, J. Boyer, E. Corse, et al. 2013. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in Tcell immunotherapy. Proc. Natl. Acad. Sci. USA 110: 6973-6978.
69. Dougan, D. A., R. L. Malby, L. C. Gruen, A. A. Kortt, and P. J. Hudson. 1998. Effects of substitutions in the binding surface of an antibody on antigen affinity. Protein Eng. 11: 65-74.
70. Baker, B. M., S. J. Gagnon, W. E. Biddison, and D. C. Wiley. 2000. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity 13: 475-484.
71. Weber, J., M. Salgaller, D. Samid, B. Johnson, M. Herlyn, N. Lassam, J. Treisman, and S. A. Rosenberg. 1994. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-29-deoxycytidine. Cancer Res. 54: 1766-1771.
72. Cole, D. K., M. Sami, D. R. Scott, P. J. Rizkallah, O. Y. Borbulevych, P. T. Todorov, R. K. Moysey, B. K. Jakobsen, J. M. Boulter, B. M. Baker, and Yi Li. 2013. Increased peptide contacts govern high affinity binding of a modified TCR whilst maintaining a native pMHC docking mode. Front. Immunol. 4: 168.
73. Robbins, P. F., Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, et al. 2008. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180: 6116-6131.
74. Ma, J. C., and D. A. Dougherty. 1997. The cation-p interaction. Chem. Rev. 97: 1303-1324.
75. Baker, B. M., D. R. Scott, S. J. Blevins, and W. F. Hawse. 2012. Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism. Immunol. Rev. 250: 10-31.
76. Pierce, B. G., J. N. Haidar, Y. Yu, and Z. Weng. 2010. Combinations of affinity-enhancing mutations in a T cell receptor reveal highly nonadditive effects within and between complementarity determining regions and chains. Biochemistry 49: 7050-7059.
77. Clark, L. A., P. A. Boriack-Sjodin, J. Eldredge, C. Fitch, B. Friedman, K. J. Hanf, M. Jarpe, S. F. Liparoto, Y. Li, A. Lugovskoy, et al. 2006. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci. 15: 949-960.
78. Kraich, M., M. Klein, E. Patiño, H. Harrer, J. Nickel, W. Sebald, and T. D. Mueller. 2006. A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor. BMC Biol. 4: 13.
79. Moza, B., R. A. Buonpane, P. Zhu, C. A. Herfst, A. K. Rahman, J. K. McCormick, D. M. Kranz, and E. J. Sundberg. 2006. Long-range cooperative binding effects in a T cell receptor variable domain. Proc. Natl. Acad. Sci. USA 103: 9867-9872.
80. Lippow, S. M., K. D. Wittrup, and B. Tidor. 2007. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat. Biotechnol. 25: 1171-1176.
81. Dunn, S. M., P. J. Rizkallah, E. Baston, T. Mahon, B. Cameron, R. Moysey, F. Gao, M. Sami, J. Boulter, Y. Li, and B. K. Jakobsen. 2006. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent crossreactivity. Protein Sci. 15: 710-721.
82. Corse, E., R. A. Gottschalk, M. Krogsgaard, and J. P. Allison. 2010. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol. 8: 100481.
83. González, P. A., L. J. Carreño, D. Coombs, J. E. Mora, E. Palmieri, B. Goldstein, S. G. Nathenson, and A. M. Kalergis. 2005. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc. Natl. Acad. Sci. USA 102: 4824-4829.
84. Thomas, S., S. A. Xue, C. R. Bangham, B. K. Jakobsen, E. C. Morris, and H. J. Stauss. 2011. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 118: 319-329.
85. Carreño, L. J., S. M. Bueno, P. Bull, S. G. Nathenson, and A. M. Kalergis. 2007. The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge. Immunology 121: 227-237.
86. McMahan, R. H., J. A. McWilliams, K. R. Jordan, S. W. Dow, D. B. Wilson, and J. E. Slansky. 2006. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J. Clin. Invest. 116: 2543-2551.
87. Kalergis, A. M., N. Boucheron, M. A. Doucey, E. Palmieri, E. C. Goyarts, Z. Vegh, I. F. Luescher, and S. G. Nathenson. 2001. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2: 229-234.
88. Irving, M., V. Zoete, M. Hebeisen, D. Schmid, P. Baumgartner, P. Guillaume, P. Romero, D. Speiser, I. Luescher, N. Rufer, and O. Michielin. 2012. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J. Biol. Chem. 287: 23068-23078.
89. Hebeisen, M., L. Baitsch, D. Presotto, P. Baumgaertner, P. Romero, O. Michielin, D. E. Speiser, and N. Rufer. 2013. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J. Clin. Invest. 123: 1044-1056.
90. Huseby, E. S., J. White, F. Crawford, T. Vass, D. Becker, C. Pinilla, P. Marrack, and J. W. Kappler. 2005. How the T cell repertoire becomes peptide and MHC specific. Cell 122: 247-260.
91. Yin, L., E. Huseby, J. Scott-Browne, K. Rubtsova, C. Pinilla, F. Crawford, P. Marrack, S. Dai, and J. W. Kappler. 2011. A single T cell receptor bound to major histocompatibility complex class I and class II glycoproteins reveals switchable TCR conformers. Immunity 35: 23-33.
92. Skipper, J. C., P. H. Gulden, R. C. Hendrickson, N. Harthun, J. A. Caldwell, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1999. Mass-spectrometric evaluation of HLA-A∗0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82: 669-677.
93. Derré, L., M. Ferber, C. Touvrey, E. Devevre, V. Zoete, A. Leimgruber, P. Romero, O. Michielin, F. Lévy, and D. E. Speiser. 2007. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J. Immunol. 179: 7635-7645.
94. Held, G., A. Wadle, N. Dauth, G. Stewart-Jones, C. Sturm, M. Thiel, C. Zwick, D. Dieckmann, G. Schuler, H. R. Hoogenboom, et al. 2007. MHC-peptidespecific antibodies reveal inefficient presentation of an HLA-A∗0201-restricted, Melan-A-derived peptide after active intracellular processing. Eur. J. Immunol. 37: 2008-2017.
95. Michaeli, Y., G. Denkberg, K. Sinik, L. Lantzy, C. Chih-Sheng, C. Beauverd, T. Ziv, P. Romero, and Y. Reiter. 2009. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J. Immunol. 182: 6328-6341.
96. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wolfel, D. Lienard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A∗0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159: 2366-2374.
97. Romero, P., D. Valmori, M. J. Pittet, A. Zippelius, D. Rimoldi, F. Lévy, V. Dutoit, M. Ayyoub, V. Rubio-Godoy, O. Michielin, et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188: 81-96.
98. Borbulevych, O. Y., F. K. Insaidoo, T. K. Baxter, D. J. Powell, Jr., L. A. Johnson, N. P. Restifo, and B. M. Baker. 2007. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J. Mol. Biol. 372: 1123-1136.
99. Brahmer, J. R. 2012. PD-1-targeted immunotherapy: recent clinical findings. Clin. Adv. Hematol. Oncol. 10: 674-675.
100. Pardoll, D., and C. Drake. 2012. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med. 209: 201-209.
101. Di Stasi, A., S. K. Tey, G. Dotti, Y. Fujita, A. Kennedy-Nasser, C. Martinez, K. Straathof, E. Liu, A. G. Durett, B. Grilley, et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365: 1673-1683.